The case against ergocalciferol (vitamin D2) as a vitamin supplement

American Journal of Clinical Nutrition

Volumn 84, Issue 4, 2006, Pages 694-697

  Houghton, Lisa A ^a   Vieth, Reinhold ^b,c  

^a ACADIA UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cholecalciferol; Ergocalciferol; Vitamin D2; Vitamin D3; Vitamin supplement

Indexed keywords

25 HYDROXYVITAMIN D; COD LIVER OIL; COLECALCIFEROL; ERGOCALCIFEROL; ERGOSTEROL; VITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; DRUG DERIVATIVE;

BINDING AFFINITY; DIET THERAPY; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; NONHUMAN; PRESCRIPTION; REVIEW; RICKETS; VITAMIN SUPPLEMENTATION; ARTICLE; BLOOD; CLINICAL TRIAL; DIET SUPPLEMENTATION; METABOLISM; PHARMACOKINETICS;

PRIMATES;

BIOLOGICAL MARKERS; CHOLECALCIFEROL; CLINICAL TRIALS; DIETARY SUPPLEMENTS; ERGOCALCIFEROLS; HUMANS; THERAPEUTIC EQUIVALENCY; VITAMIN D;

EID: 33750632195     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.4.694     Document Type: Review

References (47)

1. Committee of Revision. Drug information for the health care professional. Rockville, MD: United States Pharmacopeial Convention, Inc, 1997.
2. Institute of Medicine. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Vitamin D. Dietary reference intakes: calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997:250-87.
3. Medicines Commission. British Pharmacopoeia 1980. London, United Kingdom: Her Majesty's Stationery Office, 1980.
4. WARF Wisconsin Alumni Research Foundation. Steenbock and WARF's founding. Internet: http://www.warf.org/about/ (accessed 06 January 2006).
5. Hess AF, Lewis JM, Rivkin H. Newer aspects of the therapeutics of viosterol (irradiated ergosterol). JAMA 1930;94:1885.
6. Park EA. The therapy of rickets. JAMA 1940;115:370-9.
7. World Health Organization. Expert committee on biological standardization, report of the subcommittee on fat soluble vitamins. World Health Organ Tech Rep Ser 1950;3:7.
8. Klinke K, Bogner W, Gleiss J. Zur dosierung des Vigantol D3 bei Fruhgeborenen. [The dosing of premies with Vigantol/vitamin D3.] Deutsche Med Wochenschrift 1954;79:370-1.
9. Norman AW. Problems relating to the definition of an international unit for Vitamin D and its metabolites. J Nutr 1972;102:1243-6.
10. Specker BL, Ho ML, Oestreich A, et al. Prospective study of vitamin D supplementation and rickets in China. J Pediatr 1992;120:733-9.
11. Hoy DA, Ramberg CF, Horst RL. Evidence that discrimination against ergocalciferol by the chick is the result of enhanced metabolic clearance raes for its mono- and dihydroxylated metabolites. J Nutr 1988;118:633-8.
12. 2. J Clin Endocrinol Metab 1989;69:1282-9.
13. Horst RL, Napoli JL, Littledike ET. Discrimination in the metabolism of orally dosed ergocalciferol and cholecalciferol by the pig, rat and chick. Biochem J 1982;204:185-9.
14. Hollis BW. Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their metabolites. J Steroid Biochem 1984;21:81-6.
15. Jones G. Analog metabolism. In: Feldman D, Glorieux F, Pike JW, eds. Vitamin D. New York, NY: Elsevier Academic Press, 1997:973-94.
16. Hartwell D, Hassager C, Christiansen C. Effect of Vitamin D2 and Vitamin D3 on the serum concentrations of 1,25(OH)2D2 and 1,25(OH)2D3 in normal subjects. Acta Endocrinol (Copenh) 1987;115:378-84.
17. Whyte MP, Haddad JG Jr, Walters DD, Stamp TCB. Vitamin D bioavailability: serum 25-Hydroxyvitamin D levels in man after oral, subcutaneous, intramuscular, and intravenous vitamin D administration. J Clin Endocrinol Metab 1979;48:906-11.
18. Tjellesen L, Hummer L, Christiansen C, Rodbro P. Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner 1986;1:407-13.
19. Trang H, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998;68:854-48.
20. Mastaglia SR, Mautalen CA, Parisi MS, Oliveri B. Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women. Eur J Clin Nutr 2006;60:681-7.
21. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89:5387-91.
22. Rapuri PB, Gallagher JC, Haynatzki G. Effect of vitamins D2 and D3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcified Tissue International 2004;74:150-6.
23. Holmberg I, Berlin T, Ewerth S, Bjorkhem I. 25-Hydroxylase activity in subcellular fractions from human liver. Evidence for different rates of mitochondrial hydroxylation of vitamin D2 and D3. Scand J Clin Lab Invest 1986;46:785-90.
24. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. De-ophanization of cytochrome P450 2R1. A microsomal vitamin D 25-hydroxylase. J Biol Chem 2003;278:38084-93.
25. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004;101:7711-5.
26. Horst RL, Reinhardt TA, Reddy S. Vitamin D metabolism. In: Feldman D, Pike JW, Glorieux FH, eds. Vitamin D. London, United Kingdom: Elsevier Academic Press, 2005:15-36.
27. Horst RL, Reinhardt TA, Ramberg CF, Koszewski NJ, Napoli JL. 24-Hydroxylation of 1,25-dihydroxyergocalciferol: an unambiguous deactivation process. J Biol Chem 1986;261:9250-6.
28. Jones G, Schnoes HK, Kevan L, De Luca HF. Isolation and identification of 24-hydroxyvitamin D2 represents a minor physiological pathway for the activation of vitamin D2 in mammals. Arch Biochem Biophys 1980;202:450-7.
29. Horst RL, Koszewski NJ, Reinhardt TA. 1 alpha-hydroxylation of 24-hydroxyvitamin D2 represents a minor physiological pathway for the activation of vitamin D2 in mammals. Biochemistry 1990;29:578-82.
30. Mawer EB, Jones G, Davies M, et al. Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum. J Clin Endocrinol Metab1998;83:2156-66.
31. 3] on selected vitamin D-regulated events in the rat. Biochem Pharmacol 2000;60:701-8.
32. Harris SS, Dawson-Hughes B, Perrone GA. Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D. J Am Coll Nutr 1999;18:470-4.
33. Harris SS, Dawson-Hughes B. Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3. J Am Coll Nutr 2002;21:357-62.
34. Nordin BE, Baker MR, Horsman A, Peacock M. A prospective trial of the effect of vitamin D supplementation on metacarpal bone loss in elderly women. Am J Clin Nutr 1985;42:470-4.
35. Cooper L, Clifton-Bligh PB, Nery ML, et al. Vitamin D supplementation and bone mineral density in early postmenopausal women. Am J Clin Nutr 2003;77:1324-9.
36. Bischoff HA, Stahelin HB, Dick W et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343-51.
37. Flicker L, MacInnis RJ, Stein MS, et al. Should older people in residential care receive vitamin D to prevent falls? Results of a randomized trial. J Am Geriatr Soc 2005;53:1881-8.
38. Law M, Withers H, Morris J, Anderson F. Vitamin D supplementation and the prevention of fractures and falls: results of a randomised trial in elderly people in residential accommodation. Age Ageing 2006;35:482-6.
39. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
40. Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995;80:1052-8.
41. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, wson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64.
42. De Luca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(suppl):1689S-96S.
43. 3) at high humidity and elevated temperatures. J Pharm Sci 1980;69:1099-102.
44. Huber W, Barlow OW. Chemical and biological stability of crystalline vitamins D2 and D3 and their derivatives. J Biol Chem 1943;149:125-37.
45. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 2001;73:288-94.
46. Hollis BW. The determination of circulating 25-hydroxyvitamin D: no easy task. J Clin Endocrinol Metab 2004;89:3149-51.
47. 3 in man. In: Norman AW, Schaefer K, Grigoleit H-G, Vaamonde J, eds. Vitamin D, chemical, biochemical and clinical update. Berlin, Germany: Walter deGruyter, 1985;3-12.